<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"
  dtd-version="3.0" article-type="brief-report" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Rev Saude Publica</journal-id>
      <journal-title-group>
        <journal-title>Revista de Saúde Pública</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Rev. Saúde Pública</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0034-8910</issn>
      <issn pub-type="epub">1518-8787</issn>
      <publisher>
        <publisher-name>Faculdade de Saúde Pública da Universidade de São Paulo</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">S0034-8910.2013047004701</article-id>
      <article-id pub-id-type="doi">10.1590/S0034-8910.2013047004701</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Comunicação Breve</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="pt">Coexistência de variantes HIV-1 com inserção dipeptídica no
          gene da transcriptase reversa</article-title>
        <trans-title-group xml:lang="es">
          <trans-title>Coexistencia de variantes de VIH-1 con inserción dipeptídica en el gen de la
            transcriptasa inversa</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Tanikawa</surname>
            <given-names>Aline Aki</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">I</xref>
          <xref ref-type="aff" rid="aff4">IV</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barreto</surname>
            <given-names>Sarita Fiorelli Dias</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">II</xref>
          <xref ref-type="aff" rid="aff4">IV</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Grotto</surname>
            <given-names>Rejane Maria Tommasini</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">III</xref>
          <xref ref-type="aff" rid="aff4">IV</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pardini</surname>
            <given-names>Maria Inês de Moura Campos</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">III</xref>
          <xref ref-type="aff" rid="aff4">IV</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>I</label>
        <institution content-type="orgdiv1">Faculdade de Medicina de Botucatu</institution>
        <institution content-type="orgname">Universidade Estadual Paulista</institution>
        <addr-line>
          <named-content content-type="city">Botucatu</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <country>Brasil</country> Programa de Pós-Graduação em Fisiopatologia em Clínica Médica.
        Faculdade de Medicina de Botucatu. Universidade Estadual Paulista. Botucatu, SP, Brasil</aff>
      <aff id="aff2">
        <label>II</label>
        <institution content-type="orgdiv1">Faculdade de Medicina de Botucatu</institution>
        <institution content-type="orgname">Universidade Estadual Paulista</institution>
        <addr-line>
          <named-content content-type="city">Botucatu</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <country>Brasil</country> Programa de Pós-Graduação em Pesquisa e Desenvolvimento:
        Biotecnologia Médica. Faculdade de Medicina de Botucatu. Universidade Estadual Paulista.
        Botucatu, SP, Brasil</aff>
      <aff id="aff3">
        <label>III</label>
        <institution content-type="orgdiv2">Departamento de Clínica Médica</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina de Botucatu</institution>
        <institution content-type="orgname">Universidade Estadual Paulista</institution>
        <named-content content-type="city">Botucatu</named-content>
        <named-content content-type="state">SP</named-content>
        <country>Brasil</country> Departamento de Clínica Médica. Faculdade de Medicina de Botucatu
        . Universidade Estadual Paulista. Botucatu, SP, Brasil</aff>
      <aff id="aff4">
        <label>IV</label>
        <institution content-type="orgdiv2">Laboratório de Biologia Molecular</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina de Botucatu</institution>
        <institution content-type="orgname">Universidade Estadual Paulista</institution>
        <addr-line>
          <named-content content-type="city">Botucatu</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <country>Brasil</country> Laboratório de Biologia Molecular. Faculdade de Medicina de
        Botucatu. Universidade Estadual Paulista. Botucatu, SP, Brasil</aff>
      <author-notes>
        <corresp>
          <bold>Correspondência | Correspondence</bold> : Maria Inês de Moura Campos Pardini.
          Faculdade de Medicina de Botucatu. Laboratório de Biologia Molecular – Divisão Hemocentro.
          Distrito de Rubião Júnior, s/ n°. 18618-970 Botucatu, SP, Brasil. E-mail:
          inespardini@gmail.com</corresp>
        <fn fn-type="conflict">
          <p>Os autores declaram não haver conflito de interesses.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>08</month>
        <year>2013</year>
      </pub-date>
      <volume>47</volume>
      <issue>04</issue>
      <fpage>821</fpage>
      <lpage>823</lpage>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>12</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>4</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access"
          xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
            Commons Attribution Non-Commercial License, which permits unrestricted non-commercial
            use, distribution, and reproduction in any medium, provided the original work is
            properly cited.</license-p>
        </license>
      </permissions>
      <abstract xml:lang="pt">
        <p>O objetivo desta comunicação foi descrever a detecção de coexistência de variantes HIV-1
          com inserções de dois aminoácidos entre os códons 69 e 70 da transcriptase reversa. Tais
          variantes foram isoladas de paciente do sexo masculino, 16 anos de idade, em tratamento no
          interior do estado de São Paulo. Após confirmação de falha terapêutica, foi realizado
          teste de resistência a antirretrovirais, a partir do qual foram detectadas duas variantes
          contendo inserções dos aminoácidos Ser-Gly/Ser-Ala no códon 69 da transcriptase reversa,
          além da mutação T69S. Tais inserções possuem baixa prevalência, não foram relatadas em
          caráter de coexistência no Brasil e estão relacionadas com a resistência a múltiplas
          drogas, tornando o achado relevante do ponto de vista epidemiológico.</p>
      </abstract>
      <trans-abstract xml:lang="es">
        <p>El objetivo de ésta comunicación fue describir la detección de coexistencia de variantes
          VIH-1 con inserciones de dos aminoácidos entre los codones 69 y 70 de la transcriptasa
          inversa. Tales variantes fueron aisladas de paciente del sexo masculino, 16 años de edad,
          en tratamiento en el interior del estado de Sao Paulo. Posterior a la confirmación de la
          falla terapéutica, se realizó prueba de resistencia para antirretrovirales, a partir del
          cual se detectaron dos variantes que contenían dos inserciones de los aminoácidos
          Ser-Gly/Ser-Ala en el codón 69 de la transcriptasa inversa, además de la mutación T69S.
          Tales inserciones poseen baja prevalencia, no fueron relatadas en carácter de coexistencia
          en Brasil y están relacionadas con la resistencia a múltiples drogas, tomando el resultado
          relevante desde el punto de vista epidemiológico.</p>
      </trans-abstract>
      <kwd-group xml:lang="pt">
        <kwd>HIV-1, genética</kwd>
        <kwd>Transcriptase Reversa do HIV</kwd>
        <kwd>Proteínas do Vírus da Imunodeficiência Humana</kwd>
        <kwd>Farmacorresistência Viral Múltipla</kwd>
      </kwd-group>
      <kwd-group xml:lang="es">
        <kwd>VIH-1, genética</kwd>
        <kwd>Transcriptasa Inversa del VIH</kwd>
        <kwd>Proteínas del Virus de la Inmunodeficiencia Humana</kwd>
        <kwd>Farmacorresistencia Viral Múltiple</kwd>
      </kwd-group>
      <counts>
        <fig-count count="2"/>
        <ref-count count="5"/>
        <page-count count="3"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUÇÃO</title>
      <p>A pressão seletiva do esquema terapêutico antirretroviral (ARV) pode resultar na emergência
        de variantes resistentes, as quais pré-existem minoritariamente no paciente infectado com
        HIV. Mutações de ponto de uma ou duas bases no gene da transcriptase reversa (TR) estão
        associadas com resistência aos inibidores dessa enzima. Além disso, há relatos de que a
        resistência a múltiplos análogos nucleosídeos pode também ser resultante de diversas
        inserções/mutações existentes nos vírus. <xref ref-type="bibr" rid="B1">
          <sup>1</sup>
        </xref>
        <sup>,</sup>
        <xref ref-type="bibr" rid="B5">
          <sup>5</sup>
        </xref>
      </p>
      <p>O uso prolongado da terapia ARV com zidovudina, frequentemente junto ou seguida pela
        administração de outros inibidores nucleosídeos, está associado com a seleção de variantes
        com inserção de aminoácidos entre os resíduos 69 e 70 da TR do HIV-1. <xref ref-type="bibr"
          rid="B3">
          <sup>3</sup>
        </xref>
        <sup>,</sup>
        <xref ref-type="bibr" rid="B5">
          <sup>5</sup>
        </xref>
      </p>
      <p>O objetivo deste estudo foi descrever a detecção de coexistência de variantes HIV-1 com
        inserções de dois aminoácidos entre os códons 69 e 70 da TR.</p>
    </sec>
    <sec>
      <title>DESCRIÇÃO DO CASO</title>
      <p>Paciente do sexo masculino, 16 anos, pardo e com exposição vertical ao vírus HIV. O caso
        foi notificado em 1996 e, desde então, manteve carga viral detectável e níveis de CD4+
        baixo, sem, no entanto, desenvolver sintomas da síndrome da imunodeficiência adquirida
        (Aids). A menor contagem de linfócitos CD4+ ocorreu em 2011, 234 cels/mm <xref
          ref-type="bibr" rid="B3">
          <sup>3</sup>
        </xref> , e a carga viral no mesmo ano foi de 4,624 log. O uso de ARV teve início em 2007
        com os inibidores da TR zidovudina e didanosina, seguido da introdução de efavirenz em 2008.
        Após o compromisso de adesão do paciente, o teste de resistência a antirretrovirais (TRUGENE
          <sup>®</sup> HIV-1 <italic>Genotyping Test on an OpenGene</italic>
        <sup>®</sup>
        <italic>DNA Sequencing System, Siemens Healthcare Diagnostics</italic> , Deerfield, IL, USA)
        foi solicitado em 2011 e realizado no Laboratório de Biologia Molecular do Hemocentro da
        Faculdade de Medicina de Botucatu, Universidade Estadual Paulista (UNESP), pertencente à
        Rede Nacional de Genotipagem do HIV-1 (RENAGENO) do Ministério da Saúde.</p>
      <p>O subtipo viral caracterizado foi F1, utilizando o gene da transcriptase reversa, segundo
        análise realizada pela ferramenta REGA HIV <italic>Subtyping Tool</italic> . <xref
          ref-type="fn" rid="fn1">
          <sup>a</sup>
        </xref> A sequência obtida evidenciou a mutação T69S, seguida das inserções Ser-Gly (SG) /
        Ser-Ala (SA), o que sugere a coexistência de variantes virais com inserções de aminoácidos
        distintos no códon 69, confirmada a partir de sequências geradas por <italic>primers
          forward</italic> e <italic>reverse</italic> , segundo especificações da técnica utilizada.
        A análise do eletroferograma ( <xref ref-type="fig" rid="f01">Figura</xref> ) mostrou as
        sequências de nucleotídeos AGT e G <underline>S</underline> T, simultaneamente.</p>
      <p>
        <fig id="f01">
          <label>Figura</label>
          <caption>
            <title>Parte do eletroferograma de uma sequência genômica da região da transcriptase
              reversa do HIV-1, evidenciando a inserção de dois aminoácidos (Ser e Gly/Ala) entre os
              códons 69 e 70, a qual foi confirmada a partir de sequências geradas por
                <italic>primers forward</italic> e <italic>reverse</italic> , segundo especificações
              da técnica utilizada (TRUGENE <sup>®</sup> hiv-1 <italic>Genotyping Test on na
                OpenGene</italic>
              <sup>®</sup> DNA <italic>Sequencing System</italic> , <italic>Siemens Healthcare
                Diagnostics</italic> , <italic>Deerfield</italic> , IL, EUA).</title>
          </caption>
          <graphic xlink:href="0034-8910-rsp-47-04-0821-gf01"/>
        </fig>
      </p>
      <p>O perfil de mutação incluiu as mutações A62V, K101P/Q, K103N, V106I, V179D/E, Y188L, T215Y
        no gene da transcriptase reversa (TR), além das mutações L10I e M36I na protease. Não foi
        observada nenhuma resistência aos inibidores de protease. Em contrapartida, houve
        resistência a múltiplas drogas da classe dos inibidores de TR.</p>
      <p>A sequência obtida foi analisada utilizando o algoritmo <italic>Blast Basic Local Alignment
          Search Tool</italic> (Blast), <xref ref-type="fn" rid="fn2">
          <sup>b</sup>
        </xref> disponível no <italic>National Center for Biotechnology Information</italic> (NCBI),
        sendo constatada uma similaridade de 93%.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSÃO</title>
      <p>A inserção de dois aminoácidos entre os resíduos 69 e 70 da TR do HIV-1 por si só não
        confere resistência significativa. No entanto, quando associada às substituições, como
        T215Y, M41L, A62V ou L210W, pode ocasionar a emergência de variantes resistentes a múltiplos
        análogos de nucleosídeos. <xref ref-type="bibr" rid="B1">
          <sup>1</sup>
        </xref>
        <sup>,</sup>
        <xref ref-type="bibr" rid="B3">
          <sup>3</sup>
        </xref>
        <sup>,</sup>
        <xref ref-type="bibr" rid="B5">
          <sup>5</sup>
        </xref>
      </p>
      <p>As mutações de inserção entre os códons 69 e 70 estão presentes, com baixa prevalência
        (aproximadamente 0,5% a 2,4%), <xref ref-type="bibr" rid="B2">
          <sup>2</sup>
        </xref>
        <sup>,</sup>
        <xref ref-type="bibr" rid="B3">
          <sup>3</sup>
        </xref>
        <sup>,</sup>
        <xref ref-type="bibr" rid="B4">
          <sup>4</sup>
        </xref> em indivíduos experimentados com inibidores da TR análogos nucleosídeos, sendo mais
        comum a inserção dos dipeptídeos serina-serina, serina-arginina e serina-glicina. Tais
        rearranjos estão localizados na estrutura hairpin loop β3-β4 da TR do HIV-1 e estão
        suscetíveis à interação com o processo de ligação de nucleotídeos. <xref ref-type="bibr"
          rid="B2">
          <sup>2</sup>
        </xref>
      </p>
      <p>Em 1999, Larder et al <xref ref-type="bibr" rid="B1">
          <sup>1</sup>
        </xref> relataram que a alteração 69Ser-(Ser-Ser), por si só, demonstrou apenas uma
        diminuição significante na suscetibilidade ao 3TC. No entanto, Winters et al <xref
          ref-type="bibr" rid="B5">
          <sup>5</sup>
        </xref> (1998) reportaram que a mutação 69Ser-(Ser-Ala) ou 69Ser-(Ser-Gly), mesmo sem demais
        mutações genotípicas, conferia resistência a múltiplas drogas.</p>
      <p>A detecção da substituição única, Thr69Ser, sem inserção, sugere que a mutação possa se
        desenvolver antes da inserção de aminoácido. No entanto, ainda não é conhecido
        especificamente o mecanismo preciso para a ocorrência da inserção. <xref ref-type="bibr"
          rid="B1">
          <sup>1</sup>
        </xref>
      </p>
      <p>No Brasil, não há relatos que demonstram a presença de variantes HIV-1 com inserção de
        dipeptídeos entre os códons 69 e 70 da TR em coexistência, o que torna o achado relevante do
        ponto de vista epidemiológico, uma vez que tal inserção está relacionada com a resistência a
        múltiplos análogos de nucleosídeos e pouco se sabe sobre sua prevalência e significância
        clínica.</p>

    </sec>
  </body>
  <back>
    <ref-list>
      <title>REFERÊNCIAS</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>. Larder BA, Bloor S, Kemp SD, Kurt H, Desmet RL, Miller V, et al. A family
          of insertion mutations between codons 67 and 70 of human immunodeﬁciency virus type 1
          reverse transcriptase confer multinucleoside analog resistance. <italic>Antimicrob Agents
            Chemother.</italic> 1999;43(8):1961-7.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Larder</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Bloor</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kemp</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Kurt</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Desmet</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>V</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">A family of insertion mutations between codons 67 and 70 of
            human immunodeﬁciency virus type 1 reverse transcriptase confer multinucleoside analog
            resistance</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>1999</year>
          <volume>43</volume>
          <issue>8</issue>
          <fpage>1961</fpage>
          <lpage>1967</lpage>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation>. Masquelier B, Race E, Tamalet C, Descamps D, Izopet J, Buffet-Janvresse C,
          et al. Genotypic and phenotypic resistance patterns of human immunodeﬁciency virus type 1
          variants with insertions or deletions in the reverse transcriptase (RT): multicenter study
          of patients treated with RT inhibitors. <italic>Antimicrob Agents Chemother.</italic>
          2001;45(6):1836-42. DOI:10.1128/AAC.45.6.1836-1842.2001</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Masquelier</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Race</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tamalet</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Descamps</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Izopet</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Buffet-Janvresse</surname>
              <given-names>C</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">Genotypic and phenotypic resistance patterns of human
            immunodeﬁciency virus type 1 variants with insertions or deletions in the reverse
            transcriptase (RT): multicenter study of patients treated with RT
            inhibitors</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>2001</year>
          <volume>45</volume>
          <issue>6</issue>
          <fpage>1836</fpage>
          <lpage>1842</lpage>
          <pub-id pub-id-type="doi">10.1128/AAC.45.6.1836-1842.2001</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation>. Tamalet C, Yahi N, Tourrès C, Colson P, Quinson AM, Poizot-Martin I, et
          al. Multidrug resistance genotypes (insertions in the â3-â4 finger subdomain and MDR
          Mutations) of HIV-1 reverse transcriptase from extensively treated patients: incidence and
          association with other resistance mutations. <italic>Virology</italic> .
          2000;270(2):310-6. DOI:10.1006/viro.2000.0261</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Tamalet</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Yahi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Tourrès</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Colson</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Quinson</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Poizot-Martin</surname>
              <given-names>I</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">Multidrug resistance genotypes (insertions in the â3-â4
            finger subdomain and MDR Mutations) of HIV-1 reverse transcriptase from extensively
            treated patients: incidence and association with other resistance
            mutations</article-title>
          <source>Virology</source>
          <year>2000</year>
          <volume>270</volume>
          <issue>2</issue>
          <fpage>310</fpage>
          <lpage>316</lpage>
          <pub-id pub-id-type="doi">10.1006/viro.2000.0261</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation>. Van Vaerenbergh K, Van Laethem K, Albert J, Boucher CA, Clotet B, Floridia
          M, et al. Prevalence and characteristics of multinucleoside-resistant human
          immunodeﬁciency virus type 1 among European patients receiving combinations of nucleoside
          analogues. <italic>Antimicrob Agents Chemother</italic> . 2000;44(8):2109-17.
          DOI:10.1128/AAC.44.8.2109-2117.2000</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Van Vaerenbergh</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Van Laethem</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Albert</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Boucher</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Clotet</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Floridia</surname>
              <given-names>M</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">Prevalence and characteristics of multinucleoside-resistant
            human immunodeﬁciency virus type 1 among European patients receiving combinations of
            nucleoside analogues</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>2000</year>
          <volume>44</volume>
          <issue>8</issue>
          <fpage>2109</fpage>
          <lpage>2117</lpage>
          <pub-id pub-id-type="doi">10.1128/AAC.44.8.2109-2117.2000</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation>. Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, Shafer RW, et al. A
          6-basepair insert in the reverse transcriptase gene of human immunodeﬁciency virus type 1
          confers resistance to multiple nucleoside inhibitors. <italic>J Clin Invest.</italic>
          1998;102(10):1769-75.DOI:10.1172/JCI4948</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Winters</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Coolley</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Girard</surname>
              <given-names>YA</given-names>
            </name>
            <name>
              <surname>Levee</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Hamdan</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Shafer</surname>
              <given-names>RW</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">A 6-basepair insert in the reverse transcriptase gene of
            human immunodeﬁciency virus type 1 confers resistance to multiple nucleoside
            inhibitors</article-title>
          <source>J Clin Invest</source>
          <year>1998</year>
          <volume>102</volume>
          <issue>10</issue>
          <fpage>1769</fpage>
          <lpage>1775</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI4948</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn id="fn1">
        <label>a</label>
        <p>REGA HIV Subtyping Tool [citado 2012 nov 19]. Disponível em:
          http://www.bioafrica.net/rega-genotype/html/subtypinghiv.html</p>
      </fn>
      <fn id="fn2">
        <label>b</label>
        <p>National Center for Biotechnology Information (NCBI). Basic Local Alignment Search Tool
          (BLAST); 2012 [citado 2012 nov 20]. Disponível em:
          http://blast.ncbi.nlm.nih.gov/Blast.cgi</p>
      </fn>
    </fn-group>
  </back>
  <sub-article article-type="translation" id="TR01" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Brief Communications</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Coexistence of HIV-1 variants with dipeptidic insertion in the
          reverse transcriptase gene</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Tanikawa</surname>
            <given-names>Aline Aki</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">I</xref>
          <xref ref-type="aff" rid="aff8">IV</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barreto</surname>
            <given-names>Sarita Fiorelli Dias</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">II</xref>
          <xref ref-type="aff" rid="aff8">IV</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Grotto</surname>
            <given-names>Rejane Maria Tommasini</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">III</xref>
          <xref ref-type="aff" rid="aff8">IV</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pardini</surname>
            <given-names>Maria Inês de Moura Campos</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">III</xref>
          <xref ref-type="aff" rid="aff8">IV</xref>
        </contrib>
      </contrib-group>
      <aff id="aff5">
        <label>I</label> Programa de Pós-Graduação em Fisiopatologia em Clínica Médica. Faculdade de
        Medicina de Botucatu. Universidade Estadual Paulista. Botucatu, SP, Brasil</aff>
      <aff id="aff6">
        <label>II</label> Programa de Pós-Graduação em Pesquisa e Desenvolvimento: Biotecnologia
        Médica. Faculdade de Medicina de Botucatu. Universidade Estadual Paulista. Botucatu, SP,
        Brasil</aff>
      <aff id="aff7">
        <label>III</label> Departamento de Clínica Médica. Faculdade de Medicina de Botucatu.
        Universidade Estadual Paulista. Botucatu, SP, Brasil</aff>
      <aff id="aff8">
        <label>IV</label> Laboratório de Biologia Molecular. Faculdade de Medicina de Botucatu.
        Universidade Estadual Paulista. Botucatu, SP, Brasil</aff>
      <author-notes>
        <corresp>
          <bold>Correspondence</bold> : Maria Inês de Moura Campos Pardini Faculdade de Medicina de
          Botucatu Laboratório de Biologia Molecular – Divisão Hemocentro Distrito de Rubião Júnior,
          s/ n° 18618-970 Botucatu, SP, Brasil E-mail: inespardini@gmail.com</corresp>
        <fn fn-type="conflict">
          <p>The authors declare that there are no conflicts of interests.</p>
        </fn>
      </author-notes>
      <abstract xml:lang="en">
        <p>The aim of this communication was to describe the detection of the coexistence of HIV-1
          variant with dipeptide insertion between codons 69 and 70 of reverse transcriptase. These
          variants were isolated from a 16-year-old male patient, undergoing treatment in the city
          of Marilia, SP, Southeastern Brazil. After confirmation of treatment failure, resistance
          to antiretroviral drugs testing was performed and two variants with the insertions of the
          aminoacids Ser-Gly/Ser-Ala at codon 69 of reverse transcriptase were detected, besides the
          T69S mutation. These insertions have low prevalence, have not been reported in situations
          of coexistence in Brazil and are related to multidrug resistance, which makes this
          epidemiological finding relevant.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>HIV-1, genetics</kwd>
        <kwd>HIV Reverse Transcriptase</kwd>
        <kwd>Human Immunodeficiency Virus Proteins</kwd>
        <kwd>Drug Resistance, Multiple, Viral</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec sec-type="intro">
        <title>INTRODUCTION</title>
        <p>The selective pressure of the antiretroviral therapy (ARV) scheme may result in the
          emergence of resistant variants, which pre-exist in a minority of HIV infected patients.
          Point mutation of one or two bases in the reverse transcriptase (RT) gene are linked to
          resistance to inhibitors of this enzyme. Moreover, there are reports that resistance to
          multiple nucleoside analogs can also be the result of several insertions/mutations present
          in the viruses. <xref ref-type="bibr" rid="B1">
            <sup>1</sup>
          </xref>
          <sup>,</sup>
          <xref ref-type="bibr" rid="B5">
            <sup>5</sup>
          </xref>
        </p>
        <p>Prolonged use of ARV therapy with zidovudine, often together or followed by
          administration of other nucleoside inhibitors, is linked with the selection of variants
          with amino acid insertion between residues 69 and 70 of HIV-1 RT. <xref ref-type="bibr"
            rid="B3">
            <sup>3</sup>
          </xref>
          <sup>,</sup>
          <xref ref-type="bibr" rid="B5">
            <sup>5</sup>
          </xref>
        </p>
        <p>The aim of this study was to describe the detection of coexisting HIV-1 variants with
          insertions of two amino acids between codons 69 and 70 of RT.</p>
      </sec>
      <sec>
        <title>DESCRIPTION OF THE CASE</title>
        <p>The patient was male, aged 16, dark skinned and with vertical exposure to HIV. The case
          was reported in 1996 and, since then, the viral load remained detectable and CD4+ levels
          low without, however, developing symptoms of Acquired Immune Deficiency Syndrome (AIDS).
          The lowest CD4+ lymphocyte count occurred in 2011, 234 cels/mm <xref ref-type="bibr"
            rid="B3">
            <sup>3</sup>
          </xref> , and the viral load in that same year was 4.624 log. The administration of ARV
          drugs started in 2007 with the RT inhibitors zidovudine and didanosine, followed by the
          introduction of efavirenz in 2008. After the patient committed himself to adhering to
          treatment, antiretroviral resistance testing (TRUGENE <sup>®</sup> HIV-1 Genotyping Test
          on an OpenGene <sup>®</sup> DNA Sequencing System, Siemens Healthcare Diagnostics,
          Deerfield, IL, USA) was requested in 2011 and carried out in the Molecular Biology
          Laboratory of the Blood Transfusion Center at the Botucatu Medical School,
            <italic>Universidade Estadual Paulista</italic> (UNESP), part of the Ministry of Health
          Brazilian Network for HIV-1 Genotyping (RENAGENO).</p>
        <p>The viral subtype F1 was characterized using the reverse transcriptase gene, according to
          analysis with the REGA HIV Subtyping tool. <xref ref-type="fn" rid="fn3">
            <sup>a</sup>
          </xref> The sequence obtained showed T69S mutation, following insertions of Ser-Gly (SG) /
          Ser-Ala (SA), which suggests the coexistence of viral variants with different amino acid
          insertions at codon 69, confirmed from sequences generated by forward and reverse primers,
          according to the specifications of the technique used. Analysis of the electropherogram (
            <xref ref-type="fig" rid="f02">Figure</xref> ) showed the nucleotide sequences AGT and
          GST simultaneously.</p>
        <p>
          <fig id="f02">
            <label>Figure</label>
            <caption>
              <title>. Part of the electropherogram of a genomic sequence of the HIV-1 reverse
                transcriptase region, demonstrating the insertion of two amino acids (Ser and
                Gly/Ala) between codons 69 and 70, which was confirmed based on sequences generated
                by forward and reverse primers, according to the specifications of the technique
                used (TRUGENE <sup>®</sup> hiv-1 Genotyping Test on OpenGene <sup>®</sup> DNA
                Sequencing System, Siemens Healthcare Diagnostics, Deerfield, IL, EUA).</title>
            </caption>
            <graphic xlink:href="0034-8910-rsp-47-04-0821-gf01-en"/>
          </fig>
        </p>
        <p>The profile of mutation included A62V, K101P/Q, K103N, V106I, V179D/E, Y188L, T215Y
          mutations in the reverse transcriptase gene, as well as L10I and M36I mutations in the
          protease. No resistance to protease inhibitors was observed. In contrast, there was
          resistance to a variety of RT inhibitor drugs.</p>
        <p>The sequence obtained was analyzed using the Blast Basic Local Alignment Search Tool
          (Blast) algorithm, <xref ref-type="fn" rid="fn4">
            <sup>b</sup>
          </xref> available from the National Center for Biotechnology Information (NCBI), with a
          similarity of 93%.</p>
      </sec>
      <sec sec-type="discussion">
        <title>DISCUSSION</title>
        <p>The insertion of two amino acids alone between residues 69 and 70 of HIV-1 RT does not
          confer significant resistance. However, when combined with substitutions, such as T215Y,
          M41L, A62V or L210W, it can lead to the emergence of resistant variants to multiple
          nucleoside analogs. <xref ref-type="bibr" rid="B1">
            <sup>1</sup>
          </xref>
          <sup>,</sup>
          <xref ref-type="bibr" rid="B3">
            <sup>3</sup>
          </xref>
          <sup>,</sup>
          <xref ref-type="bibr" rid="B5">
            <sup>5</sup>
          </xref>
        </p>
        <p>Insertion mutations between codons 69 and 70 are present, with a low prevalence
          (approximately 0.5% to 2.4%), <xref ref-type="bibr" rid="B2">
            <sup>2</sup>
          </xref>
          <sup>,</sup>
          <xref ref-type="bibr" rid="B3">
            <sup>3</sup>
          </xref>
          <sup>,</sup>
          <xref ref-type="bibr" rid="B4">
            <sup>4</sup>
          </xref> in nucleoside analog reverse transcriptase inhibitors-experienced individuals, the
          most common being insertion of serine-serine, serine-arginine and serine-glycine. Such
          rearrangements are located in the structure of the β3-β4 hairpin loop of HIV-1 RT and are
          susceptible to interaction with the nucleotide binding process. <xref ref-type="bibr"
            rid="B2">
            <sup>2</sup>
          </xref>
        </p>
        <p>In 1999, Larder et al <xref ref-type="bibr" rid="B1">
            <sup>1</sup>
          </xref> reported that the 69Ser-(Ser-Ser) mutation, by itself, only showed significant
          decrease in susceptibility to 3TC. However, Winters et al <xref ref-type="bibr" rid="B5">
            <sup>5</sup>
          </xref> (1998) reported that the 69Ser-(Ser-Ala) or 69Ser-(Ser-Gly) mutation, even without
          other genotypic mutations, would confer resistance to multiple drugs.</p>
        <p>Detection of the single substitution, Thr69Ser, suggests that the mutation may develop
          before insertion of the amino acid. However, the specific mechanism required for the
          occurrence of the insertion is not known. <xref ref-type="bibr" rid="B1">
            <sup>1</sup>
          </xref>
        </p>
        <p>In Brazil, there are no reports which show the presence of HIV-1 variants with insertion
          of dipeptides between codons 69 and 70 of the RT in coexistence, which makes the finding
          relevant from an epidemiological point of view, since such insertion is related to
          resistance to multiple nucleoside analogs and little is known about its prevalence or
          clinical significance.</p>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn id="fn3">
          <label>a</label>
          <p>REGA HIV Subtyping Tool [cited 2012 Nov 19]. Available from:
            http://www.bioafrica.net/rega-genotype/html/subtypinghiv.html  </p>
        </fn>
        <fn id="fn4">
          <label>b</label>
          <p>National Center for Biotechnology Information (NCBI). Basic Local Alignment Search Tool
            (BLAST); 2012 [ cited 2012 Nov 20]. Available from:
            http://blast.ncbi.nlm.nih.gov/Blast.cgi</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
